Company Description
Ashland Inc. provides additives and specialty ingredients in the North and Latin America, Europe, Asia Pacific, and internationally.
It operates through Life Sciences, Personal Care, Specialty Additives, and Intermediates segments. The Life Sciences segment offers pharmaceutical solutions, including controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers, and tablet binders; nutrition solutions, such as thickeners, stabilizers, emulsifiers, and additives; and nutraceutical solutions comprising products for weight management, joint comfort, stomach and intestinal health, sports nutrition, and general wellness, as well as custom formulation, toll processing, and particle engineering solutions.
Its Personal Care segment provides a range of nature-based, biodegradable, and performance ingredients; solutions for toothpastes, mouth washes and rinses, denture cleaning, and care for teeth; and household supplies nature-derived rheology ingredients, biodegradable surface wetting agents, performance encapsulates, and specialty polymers.
The Specialty Additives segment offers rheology modifiers, foam control agents, surfactants and wetting agents, pH neutralizers, advanced ceramics used in catalytic converters, environmental filters, ingredients for the manufacturing of ceramic capacitors, plasma display panels and solar cells, ingredients for textile printing, thermoplastic metals, and alloys for welding.
Its Intermediates segment produces 1,4 butanediol and related derivatives, including n-methylpyrrolidone.
It offers its products to customers in a range of consumer and industrial markets, such as architectural coatings, construction, energy, food and beverage, nutraceuticals, personal care, and pharmaceutical.
The company was formerly known as Ashland Global Holdings Inc. and changed its name to Ashland Inc. in August 2022.
Ashland Inc. was founded in 1924 and is headquartered in Wilmington, Delaware.
| Country | United States |
| Founded | 1924 |
| Industry | Specialty Chemicals |
| Sector | Materials |
| Employees | 3,800 |
| CEO | Guillermo Novo |
Contact Details
Address: 8145 Blazer Drive Wilmington, Delaware 19808 United States | |
| Phone | 304-995-3000 |
| Website | ashland.com |
Stock Details
| Ticker Symbol | ASH |
| Exchange | NYSE |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001674862 |
| CUSIP Number | 044186104 |
| ISIN Number | US0441861046 |
| Employer ID | 81-2587835 |
| SIC Code | 5160 |
Key Executives
| Name | Position |
|---|---|
| Guillermo Novo | Chairman and Chief Executive Officer |
| John Kevin Willis | Senior Vice President and Chief Financial Officer |
| Dr. Osama M. Musa Ph.D. | Senior Vice President and Chief Technology Officer |
| Min S. Chong | Senior Vice President and GM of Personal Care and Specialty Additives |
| Ashok S. Kalyana | Senior Vice President and GM of Life Sciences and Intermediates |
| Karl R. Bostaph | Senior Vice President of Operations |
| Eric N. Boni | Vice President of Finance and Principal Accounting Officer |
| William C. Whitaker | Director of Investor Relations |
| Robin E. Lampkin | Senior Vice President, General Counsel and Secretary |
| Eileen M. Drury | Senior Vice President and Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2024 | 8-K | Current Report |
| Feb 26, 2024 | 8-K | Current Report |
| Feb 16, 2024 | 144 | Filing |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 9, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jan 31, 2024 | 10-Q | Quarterly Report |
| Jan 30, 2024 | 8-K | Current Report |
| Jan 26, 2024 | 8-K | Current Report |
| Jan 25, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Dec 11, 2023 | ARS | Filing |